StreetInsider.com News Articles

Amgen (AMGN) PT Lowered to $415 at BMO Capital

Mon, 12 Oct 2026 09:53:28 -0400

BMO Capital analyst Evan David Seigerman lowered the price target on Amgen (NASDAQ: AMGN) to $415.00 (from $450.00) while maintaining a Market Perform rating.

Amgen (AMGN) PT Lowered to $378 at Guggenheim

Mon, 12 Oct 2026 09:38:28 -0400

Guggenheim analyst Vamil Divan lowered the price target on Amgen (NASDAQ: AMGN) to $378.00 while maintaining a Neutral rating.

Amgen (AMGN) PT Lowered to $430 at Wells Fargo

Mon, 12 Oct 2026 06:31:38 -0400

Wells Fargo analyst Mohit Bansal lowered the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $435.00) while maintaining a Equal Weight rating.

Amgen (AMGN) PT Raised to $470 at UBS

Fri, 09 Oct 2026 09:06:22 -0400

UBS analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $470.00 (from $430.00) while maintaining a Buy rating.

Amgen (AMGN) PT Raised to $430 at RBC Capital

Thu, 08 Oct 2026 08:26:56 -0400

RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $400.00) while maintaining a Outperform rating.

Amgen (AMGN) PT Raised to $440 at Cantor Fitzgerald - 'Now a Clear Consensus Long'

Thu, 08 Oct 2026 07:11:41 -0400

Cantor Fitzgerald analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $440.00 (from $400.00) while maintaining a Neutral rating.

The analyst commented, "Now a clear consensus long, it will be important that the recent commercial upside across the core portfolio persists through 2H. We think it will, but there’s debate over whether that will be sufficient for the momentum to continue into MariTide top-line data in 1H27. Specifically, we are looking toward (1) additional pipeline updates (clarity on Sjogren’s profile, second study top-line, etc.) and/or (2) insight into ’27 outlook themes (key brand growth outlooks, margin expansion)."

Amgen (AMGN) PT Raised to $440 at Cantor Fitzgerald - 'Now a Clear Consensus Long'

Thu, 08 Oct 2026 07:11:41 -0400

Cantor Fitzgerald analyst Carter Gould raised the price target on Amgen (NASDAQ: AMGN) to $440.00 (from $400.00) while maintaining a Neutral rating.

Amgen (AMGN) PT Raised to $380 at Truist Securities

Wed, 07 Oct 2026 08:53:53 -0400

(Updated - October 7, 2026 8:53 AM EDT)

Truist Securities analyst Greg Renza raised the price target on Amgen (NASDAQ: AMGN) to $380.00 (from $362.00) while maintaining a Hold rating.

The analyst commented: "We anticipate 3Q26 total revenue of $10,227M (aligned to cons. $10,047M) and non-GAAP EPS of $5.90 (vs. cons. $5.79) for AMGN. For key franchises, our 3Q26 sales estimates are $555M (above cons. $546M) for Tezspire, $604M (above cons. $580M) for Tepezza, $1,012M (vs. cons. $1,013M) for Repatha and $360M (vs. cons. $364M) for Uplizna. For pipeline wins, we incorporated revenue contribution for dazodalibep ("dazo") in systemic Sjögren's (OASIZ 301)

Amgen (AMGN) PT Raised to $380 at Truist Securities

Wed, 07 Oct 2026 08:53:53 -0400

(Updated - October 7, 2026 8:53 AM EDT)

Truist Securities analyst Greg Renza raised the price target on Amgen (NASDAQ: AMGN) to $380.00 (from $362.00) while maintaining a Hold rating.

Amgen (AMGN) PT Lowered to $359 at Morgan Stanley

Wed, 07 Oct 2026 07:58:08 -0400

Morgan Stanley analyst Terance Flynn lowered the price target on Amgen (NASDAQ: AMGN) to $359.00 (from $362.00) while maintaining a Equalweight rating.

Amgen (AMGN) Reiterated at Neutral by Cantor Fitzgerald

Mon, 05 Oct 2026 10:05:49 -0400

(Updated - October 5, 2026 10:05 AM EDT)

Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $400.00 price target on Amgen (NASDAQ: AMGN).

The analyst commented, "On the back of solid commercial execution, Lp(a) expectations reset post-HORIZON, and positive Sjogren’s data, AMGN has returned to being a consensus long. With an otherwise tame catalyst calendar into YE26, however, much of the discussion has revolved around how investors get paid from here."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $403.04 yesterday.

Amgen (AMGN) PT Raised to $500 at Scotiabank

Tue, 29 Sep 2026 07:23:25 -0400

Scotiabank analyst Louis Chen raised the price target on Amgen (NASDAQ: AMGN) to $500.00 (from $450.00) while maintaining a Sector Outperform rating.

Canaccord Reiterates Hold Rating on Amgen (AMGN)

Wed, 23 Sep 2026 06:38:22 -0400

Canaccord analyst Gary Nachman reiterated a Hold rating and $384.00 price target on Amgen (NASDAQ: AMGN).

The analyst commented: "AMGN announced positive topline results from the first of two Ph3 trials of dazodalibep in moderate-to-severe Sjogren's disease (SjD), a solid win for its pipeline. Dazodalibep (potential first-in-class CD40L antagonist fusion protein) met the primary endpoint in the OASIZ 301 Ph3 trial that evaluated patients with SjD with moderate-to-severe systemic disease activity. It demonstrated a statistically significant and clinically meaningful improvement in change from baseline in ESSDAI at Week 48, with improvements observed as early as Week 4 and sustained through Week

Amgen (AMGN) PT Raised to $410 at Jefferies

Wed, 23 Sep 2026 05:27:52 -0400

Jefferies analyst Akash Tewari raised the price target on Amgen (NASDAQ: AMGN) to $410.00 (from $367.00) while maintaining a Hold rating.

The analyst comments "Dazodalibep (AMGN's CD40L antagonist) Ph3 in mod-severe systemic Sjögren's disease hit. We'll note: 1) Dazo improved ESSDAI as early as wk4, vs. the wk12-16 separation seen in IAN's NEPTUNUS Ph3s, 2) potentially better safety/tolerability vs. other data sets in the space. Based on the current data, we are getting incrementally more positive going into the OASIZ-303 trial (Dazo in symptomatic SjD pop; expt'ed in Q4'26).Dazo PS: ~$1Bn → $4.5Bn. PT: $367 → $410."

Amgen (AMGN) PT Raised to $410 at Jefferies

Wed, 23 Sep 2026 05:27:52 -0400

Jefferies analyst Akash Tewari raised the price target on Amgen (NASDAQ: AMGN) to $410.00 (from $367.00) while maintaining a Hold rating.

Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)

Wed, 23 Sep 2026 05:24:23 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $450.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "AMGN shares were up 4.3% on 09/22 (vs. NBI: +1.7%) as the company announced positive results from the first Ph3 study, OASIZ 301, evaluating dazodalibep (DAZ) in patients with systemic Sjögren's disease. We view the update as encouraging given the hard-to-treat nature of the disease and believe it provides a favorable setup for the upcoming OASIZ 303 study (expected to complete in 4Q) in a somewhat different patient population, which could ultimately provide important differentiation for DAZ vs. other emerging therapies including

Amgen's dazodalibep meets primary endpoint in Sjögren's Phase 3 trial

Tue, 22 Sep 2026 09:02:19 -0400

Amgen (NASDAQ: AMGN) announced that its Phase 3 OASIZ 301 study evaluating dazodalibep in adults with moderate-to-severe systemic Sjögren's disease met its primary endpoint, according to a company press release.

The study measured change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48, a validated tool used to assess systemic disease activity across organ systems. The trial enrolled approximately 621 patients with an ESSDAI score of five or higher. Improvements in ESSDAI were observed as early as Week 4 and were sustained through Week 48.

Dazodalibep is described as a CD40L antagonist fusion protein designed to

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Tue, 22 Sep 2026 09:00:00 -0400

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity

Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease

THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Tue, 22 Sep 2026 09:00:00 -0400

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity

Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease

THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

Investing.com -- Swiss drugmaker Roche announced Tuesday that its experimental obesity treatment helped patients with type 2 diabetes reduce blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial.

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Amgen (AMGN) PT Lowered to $430 at UBS

Thu, 17 Sep 2026 08:28:37 -0400

UBS analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $440.00) while maintaining a Buy rating.

The analyst commented, "We reduce our PT to $430 from $440, applying a ~17x multiple (vs. ~18x previously) to our 2027E EPS of $24.91, reflecting a lower PoS for olpasiran following NVS' pelacarsen Lp(a) missing the MACE-4 endpoint in the Phase III HORIZON CVOT."

Amgen (AMGN) PT Lowered to $430 at UBS

Thu, 17 Sep 2026 08:28:37 -0400

UBS analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $440.00) while maintaining a Buy rating.